Evidence map›Paper›PMID 41426160›Full record

ArticleSouth Asian journal of cancer2025

Consensus Statements for Clinical Practice in Advanced/Metastatic Colorectal Cancers in India Using a Modified Delphi Method.

Anant Ramaswamy, Sujay Srinivas, Viraj Lavingia, Mounika Boppana, Chakor Vora, Randeep Singh, M Vamshi Krishna, Amish Vora, Sujith Kumar Mullapally, Prabhat Bhargava and 34 more

Abstract read
In one paragraph

Article in South Asian journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors.

Anant RamaswamyDepartment of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India.
Sujay SrinivasDepartment of Medical Oncology, Bharath Hospital, Kottayam, Kerala, India.
Viraj LavingiaDepartment of Medical Oncology, Shalby Hospital, Ahmedabad, Gujarat, India.ORCID 0000-0003-1981-2693
Mounika BoppanaDepartment of Medical Oncology and Haematoncology, Krishna Institute of Medical Sciences (KIMS) Hospital, Secunderabad, Hyderabad, Telangana, India.
Chakor VoraDepartment of Medical Oncology, Sassoon General Hospital, Pune, India.
Randeep SinghDepartment of Medical and Hemato-Oncology, Narayana Health, Gurugram, Haryana, India.
M Vamshi KrishnaDepartment of Medical Oncology and Haematology, Institute of Oncology AIG Hospitals, Hyderabad, Telangana, India.
Amish VoraDepartment of Medical Oncology, H.O.P.E. Oncology Clinic, New Delhi, India.
Sujith Kumar MullapallyDepartment of Medical Oncology, Apollo Proton Cancer Centre, Chennai, Tamil Nadu, India.ORCID 0000-0003-2932-2663
Prabhat BhargavaDepartment of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India.ORCID 0000-0002-6440-2186
Vinayak MakaDepartment of Medical Oncology, Ramaiah Medical College, Bengaluru, Karnataka, India.
Gautam GoyalDepartment of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Mohali, India.
Vivek AgarwalaDepartment of Medical Oncology and Hemato-Oncology, Narayana Health, Kolkata, Bengal, India.ORCID 0000-0003-1381-0320
Ashay KarpeDepartment of Medical Oncology, Sunrise Oncology Centre, Mumbai, Maharashtra, India.
Jimmy MiraniDepartment of Medical Oncology, Wockhardt Hospital, Mumbai Central, Maharashtra, India.
S Krupa ShankarDepartment of Medical Oncology, NSR CanKure Center, Coimbatore, Tamil Nadu, India.
Tanmoy Kumar MandalDepartment of Medical Oncology, AMRI Hospital, Dhakuria, Kolkata, West Bengal, India.
Sourav Kumar MishraDepartment of Medical Oncology/Hematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Nisar Ahmad SyedDepartment of Medical Oncology, Sheri Kashmir Institute of Medical Sciences SKIMS, Soura, Jammu and Kashmir, India.
Atul SharmaDepartment of Medical Oncology and Hemato-Oncology, Max Super Specialty Hospital, Saket, New Delhi, India.
Shasanka Sekhar DasDepartment of Medical Oncology, HCG EKO Cancer Center, Kolkata, West Bengal, India.
Soumya Surath PandaDepartment of Medical Oncology, IMS & SUM Hospital, Bhubaneswar, Odisha, India.ORCID 0000-0003-2190-1927
Pradip Kumar MondalDepartment of Medical Oncology, Medica Super Specialty Hospital Mukundapur, Kolkata, West Bengal, India.
Amit KumarDepartment of Medical Oncology and Hemato-Oncology, Jay Prabha Medanta Super Specialty Hospital, Patna, Bihar, India.
Shekar PatilDepartment of Medical Oncology, HCG Hospital Bangalore, Karnataka, India.
Rakesh PinnintiDepartment of Medical Oncology, Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, Telangana, India.
Ajoy Oommen JohnDepartment of Medical Oncology, CMC Vellore, Ranipet Campus, Vellore, Tamil Nadu, India.
Murtaza BohraDepartment of Medical Oncology, National Cancer Institute, Nagpur, India.
Rejiv RajendranathDepartment of Medical Oncology, Integrated Cancer Care Group, GEM Hospital, Institute of Gastroenterology and Laparoscopy, Chennai, Tamil Nadu, India.
Sudeep DasDepartment of Medical and Hemato-Oncology, Medica Superspecialty Hospital, Mukundapur, Kolkata, West Bengal, India.
Sumit GoyalDepartment of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Rohini, Delhi, India.
Rakesh M PDepartment of Medical Oncology, Amrita Institute of Medical Sciences, Kerala, India.
Krishnakumar RathnamDepartment of Medical Oncology, Meenakshi Mission Hospital, Chinthamani Madurai, Tamil Nadu, India.
Amol PatelDepartment of Medical Oncology, Command Hospital, Central Command, Lucknow, Uttar Pradesh, India.ORCID 0000-0002-9516-8935
Boman DhabharDepartment of Medical Oncology, Fortis Hospital Mulund, Mumbai, Maharashtra, India.
Aditi ThankyDepartment of Medical Oncology, Sterling Hospital, Rajkot, Gujarat, India.
Vipul DoshiDepartment of Medical Oncology, Solapur Cancer Centre, Solapur, India.
Akhil KapoorHomi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Homi Bhabha National Institute, Varanasi.ORCID 0000-0001-6006-2631
Nishitha ShettyDepartment of Medical Oncology, Father Muller Medical College, Mangalore, Karnataka, India.
Davinder PaulDepartment of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India.
Jacob GeorgeDepartment of Medical Oncology, Manipal Hospital, Panaji, Goa, India.
Akshay D BahetiDepartment of Radiodiagnosis, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India.
Rahul KrishnatryDepartment of Radiation Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India.ORCID 0000-0003-4511-7782
Vikas OstwalDepartment of Medical Oncology, Tata Memorial Hospital (Homi Bhabha National Institute), Mumbai, Maharashtra India.ORCID 0000-0002-0067-4748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Colorectal cancer (CRC) is one of the most common malignancies across the world and is the fourth most common cancer among men in India as per the Global Cancer Observatory (GLOBOCAN) data 2020. Available data suggest that approximately 30% of patients present with advanced/metastatic CRC (mCRC). This publication summarizes the latest evidence with cognizance of the unique challenges faced in India by medical oncologists treating mCRC. Methods: A panel of 38 medical oncologists held a meeting in February 2023 and reviewed the evidence available for the management of mCRC. The meeting concentrated on the recognition and management of mCRC with a focus on systemic therapeutic approaches. A literature review of these aspects of management leads to the formation of consensus statements with the level of evidence and grades of recommendation. Statements were evaluated by the modified Delphi method. Key Content and Findings: The panel comprising 38 experts formulated 51 consensus statements with regard to the management of mCRC, including oligometastatic CRC, unresectable CRC, as well as various systemic therapeutic options. Resource-constrained scenarios, specifically with regard to the economic constraints and availability of drugs in India, were evaluated as part of the statements. Conclusion: Our consensus statements offer practical, yet evidence-based management guidelines for treating mCRC in the Indian context. Stratifying and recommending treatment options in a resource-constrained scenario is an important aspect of these statements.

Indexed as

India specificmetastatic colorectal cancermodified Delphi consensus

Identifiers

PMID41426160
PMCPMC12714484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.